I fase III- forsøgene blev INTELENCE givet til seks patienter i alderen 65 år eller derover og 53 patienter i alderen 56- 64 år.
Elderly Experience in geriatric patients is limited: in the Phase III trials, 6 patients aged 65 years or older and 53 patients aged 56-64 years received INTELENCE.